| Old Articles: <Older 4841-4850 Newer> |
|---|
 |
The Motley Fool
May 14, 2008
Brian Lawler |
Teaching Old Drugs New Tricks Pfizer's top drugs post mixed results in recent off-label studies.   |
The Motley Fool
May 14, 2008
Brian Orelli |
Abbott Knocks Down Boston Scientific Abbott Labs proves its drug-eluting device works better than its competitors as it presented more data from its ongoing Spirit III trial. |
The Motley Fool
May 13, 2008
Brian Lawler |
Sanofi Can't Shake the Generics A new threat to the pharmaceutical's top drug may have arrived. |
The Motley Fool
May 13, 2008
Rich Duprey |
Healthways Doesn't Need a Ventilator Several temporary setbacks have been reflected in Healthways' stock, which has tumbled more than 50% this year. |
The Motley Fool
May 13, 2008
Brian Orelli |
Is Merck Keeping Its Enemies Close? The drugmaker strikes a deal with an Indian generic company. |
The Motley Fool
May 13, 2008
Brian Orelli |
Omrix's Wild Ride High-growth stocks like Omrix Pharmaceutical can be hard to value. Not only are growing revenues hard to predict, but expenses can fluctuate wildly as the company grows. |
The Motley Fool
May 12, 2008
Brian Orelli |
Merging Mylan Meanders Through 2008 In the larger-is-better world of generic-drug makers, it's kind of surprising that investors haven't yet gotten behind the Mylan/Merck KGaA deal. |
The Motley Fool
May 12, 2008
Brian Orelli |
Lowering the Barr Barr Pharmaceuticals disappoints by lowering expectations. |
The Motley Fool
May 12, 2008
Brian Lawler |
Hep C Drugs Slug It Out Does Vertex's telaprevir really trump Schering's boceprevir? |
Popular Mechanics
May 8, 2008
Chris Ladd |
Autonomous 3D Robot Doc Gets X-Ray Powers With DIY A.I. Looks like the robotic uprising could be headed for the OR after all: Bots can now see through your flesh in three dimensions and direct a mechanical arm to perform a biopsy. |
| <Older 4841-4850 Newer> Return to current articles. |
